A citation-based method for searching scientific literature

Eduardo de Pablo-Fernández, Robert Courtney, Alice Rockliffe, Steve Gentleman, Janice L Holton, Thomas T Warner. Neuropathol Appl Neurobiol 2021
Times Cited: 3







List of co-cited articles
21 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6-OHDA model of Parkinson's disease.
Farideh Iravanpour, Leila Dargahi, Mohsen Rezaei, Masoud Haghani, Reza Heidari, Neda Valian, Abolhassan Ahmadiani. CNS Neurosci Ther 2021
8
66

Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
Ruth Brauer, Li Wei, Tiantian Ma, Dilan Athauda, Christine Girges, Nirosen Vijiaratnam, Grace Auld, Cate Whittlesea, Ian Wong, Tom Foltynie. Brain 2020
49
66

Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson's disease.
Istvan Horvath, Pernilla Wittung-Stafshede. Proc Natl Acad Sci U S A 2016
85
66

Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
Chien-Tai Hong, Kai-Yun Chen, Weu Wang, Jing-Yuan Chiu, Dean Wu, Tsu-Yi Chao, Chaur-Jong Hu, Kai-Yin David Chau, Oluwaseun Adebayo Bamodu. Cells 2020
38
66

Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.
Philippe Huot, Tom H Johnston, Susan H Fox, Jonathan M Brotchie. Synapse 2015
7
66



Clinical features of Parkinson disease when onset of diabetes came first: A case-control study.
E Cereda, M Barichella, E Cassani, R Caccialanza, G Pezzoli. Neurology 2012
93
66

Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging.
Young-Kyoung Ryu, Jun Go, Hye-Yeon Park, Young-Keun Choi, Yun Jeong Seo, Jung Hyeon Choi, Myungchull Rhee, Tae Geol Lee, Chul-Ho Lee, Kyoung-Shim Kim. Neuropharmacology 2020
25
66

The Relevance of Insulin Action in the Dopaminergic System.
Francesca Fiory, Giuseppe Perruolo, Ilaria Cimmino, Serena Cabaro, Francesca Chiara Pignalosa, Claudia Miele, Francesco Beguinot, Pietro Formisano, Francesco Oriente. Front Neurosci 2019
37
66

Diabetes mellitus and Parkinson disease.
Gennaro Pagano, Sotirios Polychronis, Heather Wilson, Beniamino Giordano, Nicola Ferrara, Flavia Niccolini, Marios Politis. Neurology 2018
99
66

Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies.
Ivan Martinez-Valbuena, Irene Amat-Villegas, Rafael Valenti-Azcarate, Maria Del Mar Carmona-Abellan, Irene Marcilla, Maria-Teresa Tuñon, Maria-Rosario Luquin. Acta Neuropathol 2018
36
66

Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
291
66


Disrupted Mitochondrial and Metabolic Plasticity Underlie Comorbidity between Age-Related and Degenerative Disorders as Parkinson Disease and Type 2 Diabetes Mellitus.
Diana Luz Juárez-Flores, Mario Ezquerra, Ïngrid Gonzàlez-Casacuberta, Aida Ormazabal, Constanza Morén, Eduardo Tolosa, Raquel Fucho, Mariona Guitart-Mampel, Mercedes Casado, Francesc Valldeoriola,[...]. Antioxidants (Basel) 2020
6
66

Insulin resistance in brain alters dopamine turnover and causes behavioral disorders.
Andre Kleinridders, Weikang Cai, Laura Cappellucci, Armen Ghazarian, William R Collins, Sara G Vienberg, Emmanuel N Pothos, C Ronald Kahn. Proc Natl Acad Sci U S A 2015
217
66

Saxagliptin: a novel antiparkinsonian approach.
Noha N Nassar, Muhammad Y Al-Shorbagy, Hany H Arab, Dalaal M Abdallah. Neuropharmacology 2015
63
66

Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study.
Eduardo De Pablo-Fernandez, Raph Goldacre, Julia Pakpoor, Alastair J Noyce, Thomas T Warner. Neurology 2018
114
66

Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
Harneek Chohan, Konstantin Senkevich, Radhika K Patel, Jonathan P Bestwick, Benjamin M Jacobs, Sara Bandres Ciga, Ziv Gan-Or, Alastair J Noyce. Mov Disord 2021
30
66

Mitochondrial complex I deficiency in Parkinson's disease.
A H Schapira, J M Cooper, D Dexter, J B Clark, P Jenner, C D Marsden. J Neurochem 1990
66

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.
Giovanna Muscogiuri, Ralph A DeFronzo, Amalia Gastaldelli, Jens J Holst. Trends Endocrinol Metab 2017
65
33

Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
A Vella, P Shah, A S Reed, A S Adkins, R Basu, R A Rizza. Diabetologia 2002
81
33


Inhibition of AGEs/RAGE/Rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-κB pathway.
Jingkao Chen, Zhaowei Sun, Minghua Jin, Yalin Tu, Shengnan Wang, Xiaohong Yang, Qiuhe Chen, Xiao Zhang, Yifan Han, Rongbiao Pi. J Neuroimmunol 2017
66
33


Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus.
Y-Hu Chang, S-J Yen, Y-Ha Chang, W-J Wu, K-D Lin. Eur J Neurol 2021
8
33

Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.
Per Svenningsson, Karin Wirdefeldt, Li Yin, Fang Fang, Ioanna Markaki, Suad Efendic, Jonas F Ludvigsson. Mov Disord 2016
44
33

Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis.
Emanuele Cereda, Michela Barichella, Carlo Pedrolli, Catherine Klersy, Erica Cassani, Riccardo Caccialanza, Gianni Pezzoli. Diabetes Care 2011
139
33

Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.
Amjad Abuirmeileh, Alexander Harkavyi, Nazir Rampersaud, Rebecca Lever, John A Tadross, Stephen R Bloom, Peter S Whitton. J Pharm Pharmacol 2012
24
33

Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease.
Seong Ho Jeong, Seok Jong Chung, Han Soo Yoo, Namki Hong, Jin Ho Jung, Kyoungwon Baik, Yang Hyun Lee, Young H Sohn, Phil Hyu Lee. Brain 2021
14
33

Thiazolidinedione use is associated with reduced risk of Parkinson's disease in patients with diabetes: a meta-analysis of real-world evidence.
Salman Hussain, Ambrish Singh, Harveen Baxi, Bruce Taylor, John Burgess, Benny Antony. Neurol Sci 2020
12
33

Anti-incretin, Anti-proliferative Action of Dopamine on β-Cells.
Antonella Maffei, Ann Marie Segal, Juan Carlos Alvarez-Perez, Adolfo Garcia-Ocaña, Paul E Harris. Mol Endocrinol 2015
29
33

GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Olivia M Farr, Michail Sofopoulos, Michael A Tsoukas, Fadime Dincer, Bindiya Thakkar, Ayse Sahin-Efe, Andreas Filippaios, Jennifer Bowers, Alexandra Srnka, Anna Gavrieli,[...]. Diabetologia 2016
122
33

Post hoc analysis of the Exenatide-PD trial-Factors that predict response.
Dilan Athauda, Kate Maclagan, Natalia Budnik, Luca Zampedri, Steve Hibbert, Iciar Aviles-Olmos, Kashfia Chowdhury, Simon S Skene, Patricia Limousin, Thomas Foltynie. Eur J Neurosci 2019
32
33

Diabetes Mellitus is Associated with a Higher Relative Risk for Parkinson's Disease in Women than in Men.
Carola Deischinger, Elma Dervic, Michaela Kaleta, Peter Klimek, Alexandra Kautzky-Willer. J Parkinsons Dis 2021
5
33

Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies.
Xuejing Yue, Hehua Li, Haiqing Yan, Ping Zhang, Li Chang, Tong Li. Medicine (Baltimore) 2016
81
33

Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats.
Irina Filchenko, Anna Simanenkova, Svetlana Chefu, Maria Kolpakova, Timur Vlasov. Diab Vasc Dis Res 2018
16
33

Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner.
Sandeep K Sharma, Erik Chorell, Pär Steneberg, Emma Vernersson-Lindahl, Helena Edlund, Pernilla Wittung-Stafshede. Sci Rep 2015
61
33

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
361
33

Long-term liraglutide ameliorates nigrostriatal impairment via regulating AMPK/PGC-1a signaling in diabetic mice.
Delin Ma, Xiaming Liu, Juanhong Liu, Mengni Li, Li Chen, Ming Gao, Weijie Xu, Yan Yang. Brain Res 2019
12
33

A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Ziyue Yuan, Dongfang Li, Peng Feng, Guofang Xue, Chenhui Ji, Guanglai Li, Christian Hölscher. Eur J Pharmacol 2017
58
33

Actions of β-amyloid protein on human neurons are expressed through the amylin receptor.
Jack H Jhamandas, Zongming Li, David Westaway, Jing Yang, Simran Jassar, David MacTavish. Am J Pathol 2011
67
33

Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
Augusta Pisanu, Daniela Lecca, Giovanna Mulas, Jadwiga Wardas, Gabriella Simbula, Saturnino Spiga, Anna R Carta. Neurobiol Dis 2014
166
33

A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
Dong Seok Kim, Ho-Il Choi, Yun Wang, Yu Luo, Barry J Hoffer, Nigel H Greig. Cell Transplant 2017
76
33


Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects.
Caterina Palleria, Antonio Leo, Francesco Andreozzi, Rita Citraro, Michelangelo Iannone, Rosangela Spiga, Giorgio Sesti, Andrew Constanti, Giovambattista De Sarro, Franco Arturi,[...]. Behav Brain Res 2017
56
33

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
172
33

Effect of diabetes control status on the progression of Parkinson's disease: A prospective study.
Ruwei Ou, Qianqian Wei, Yanbing Hou, Lingyu Zhang, Kuncheng Liu, Junyu Lin, Zheng Jiang, Wei Song, Bei Cao, Huifang Shang. Ann Clin Transl Neurol 2021
5
33

Insulin-Like Growth Factor-1 and Neuroinflammation.
Jose L Labandeira-Garcia, Maria A Costa-Besada, Carmen M Labandeira, Begoña Villar-Cheda, Ana I Rodríguez-Perez. Front Aging Neurosci 2017
94
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.